Results 91 to 100 of about 3,598,763 (344)

The effectiveness of oral anti-SARS-CoV-2 agents in non-hospitalized COVID-19 patients with nonalcoholic fatty liver disease: a retrospective study

Frontiers in Pharmacology
Background: The effectiveness of the novel oral antiviral agents, nirmatrelvir plus ritonavir and molnupiravir, in treating COVID-19 in patients with nonalcoholic fatty liver disease is unclear.Objective: To assess the effectiveness of novel oral ...
Chun-Chi Yang, Ya-Wen Tsai, Ya-Wen Tsai, Su-Hung Wang, Jheng-Yan Wu, Ting-Hui Liu, Wan-Hsuan Hsu, Po-Yu Huang, Min-Hsiang Chuang, Ming-Jen Sheu, Chih-Cheng Lai, Chih-Cheng Lai   +11 more
doaj   +1 more source

The Signaling Pathways, and Therapeutic Targets of Antiviral Agents: Focusing on the Antiviral Approaches and Clinical Perspectives of Anthocyanins in the Management of Viral Diseases

Frontiers in Pharmacology, 2019
As the leading cause of death worldwide, viruses significantly affect global health. Despite the rapid progress in human healthcare, there are few viricidal and antiviral therapies that are efficient enough.
Pardis Mohammadi Pour, S. Fakhri, S. Asgary, M. Farzaei, J. Echeverría   +4 more
semanticscholar   +1 more source

Antiviral agents, glucocorticoids, antibiotics, and intravenous immunoglobulin usage in 1142 patients with coronavirus disease 2019: a systematic review and meta-analysis.

Polish Archives of Internal Medicine, 2020
INTRODUCTION Treatment effects of antiviral agents, glucocorticoids, antibiotics, and intravenous immunoglobulin are controversial in patients with Coronavirus disease 2019 (COVID-19).
Lei Pei, Sheng Zhang, Linxi Huang, Xuqiang Geng, Lin-hao Ma, Weiwei Jiang, Wen-fang Li, Dechang Chen   +7 more
semanticscholar   +1 more source

Interferon-Free Regimens and Direct-Acting Antiviral Agents for Delta Hepatitis: Are We There Yet? [PDF]

, 2023
Roxana Nemțeanu, Andreea Clim, Corina Elena Hincu, Liliana Gheorghe, Irina Ciortescu, Alina Pleşa   +5 more
openalex   +1 more source

Redefining Therapies for Drug‐Resistant Tuberculosis: Synergistic Effects of Antimicrobial Peptides, Nanotechnology, and Computational Design

Advanced Healthcare Materials, EarlyView.
Antimicrobial peptide (AMP)‐loaded nanocarriers provide a multifunctional strategy to combat drug‐resistant Mycobacterium tuberculosis. By enhancing intracellular delivery, bypassing efflux pumps, and disrupting bacterial membranes, this platform restores phagolysosome fusion and macrophage function.
Christian S. Carnero Canales, Jessica Ingrid Marquez Cazorla, Renzo Marianito Marquez Cazorla, Aline Martins dos Santos, Jonatas Lobato Duarte, Letícia Oliveira Catarin Nunes, Túlio Custódio Reis, Lara Cerazi Salvador, Norival Alves Santos‐Filho, Rafael Miguel Sábio, Hélder A. Santos, Fernando Rogério Pavan   +11 more
wiley   +1 more source

Novel Nucleoside Analogues as Effective Antiviral Agents for Zika Virus Infections

Molecules, 2020
Previously considered a neglected flavivirus, Zika virus has recently emerged as a public health concern due to its ability to spread rapidly and cause severe neurological disorders, such as microcephaly in newborn babies from infected mothers, and ...
Marcella Bassetto, Cecilia M. Cima, Mattia Basso, Martina Salerno, Frank Schwarze, Daniela Friese, Joachim J. Bugert, Andrea Brancale   +7 more
doaj   +1 more source

Discovery of Dithioacetal Derivatives Containing Sulfonamide Moiety of Novel Antiviral Agents by TMV Coat Protein as a Potential Target [PDF]

, 2020
Yuyuan Yang, Jian Zhang, Xiangyang Li, Fangcheng He, Rong Wu, Deyu Hu, Baoan Song   +6 more
openalex   +1 more source

Evaluating the Antiviral Efficacy of Encapsulated PKC Inhibitor BIM‐I against influenza A Virus Infection

Advanced Healthcare Materials, EarlyView.
This study explores nanoparticle delivery of the protein kinase C inhibitor bisindolylmaleimide‐I (BIM‐I) to combat influenza A virus infections. Encapsulation in biodegradable PLGA nanoparticles improved safety while maintaining the compound's strong antiviral activity.
Laura Klement, Jana Ismail, Josefine Schroeder, Amod Godbole, Johanna Schreiber, Christine Weber, Zoltan Cseresnyes, Marc T. Figge, Bettina Löffler, Ulrich S. Schubert, Stephanie Schubert, Christina Ehrhardt, Carsten Hoffmann   +12 more
wiley   +1 more source

Clinical effectiveness of oral antiviral treatment for non-hospitalized high-risk patients with COVID-19 during Omicron JN.1 subvariant wave: a US-based propensity-matched cohort study

Pneumonia
Background This real-world study aimed to assess the effectiveness of novel oral antiviral agents in managing COVID-19 among high-risk patients during the Omicron JN.1 subvariant wave.
Wan-Hsuan Hsu, Bo-Wen Shiau, Po-Yu Huang, Ya-Wen Tsai, Jheng-Yan Wu, Ting-Hui Liu, Min-Hsiang Chuang, Shu-Farn Tey, Lun-Wu Hung, Chih-Cheng Lai   +9 more
doaj   +1 more source

Pregenomic RNA Launch Hepatitis B Virus Replication System Facilitates the Mechanistic Study of Antiviral Agents and Drug-Resistant Variants on Covalently Closed Circular DNA Synthesis

, 2022
Qiong Zhao, Jinhong Chang, René Rijnbrand, Angela M. Lam, Michael J. Sofia, Andrea Cuconati, Ju‐Tao Guo   +6 more
openalex   +2 more sources